Literature DB >> 6655566

Reduced clofibric acid clearance in renal dysfunction is due to a futile cycle.

P J Meffin, D M Zilm, J R Veenendaal.   

Abstract

Although clofibric acid is cleared predominantly by formation of an ester glucuronide, its plasma clearance is reduced in renal dysfunction. The mechanism of this phenomenon has been investigated in rabbits in which uranyl nitrate administration (0.0625-0.5 mg/kg) produced a dose-dependent decrease in creatinine clearance and clofibric acid plasma clearance. Uranyl nitrate doses of 0.3 mg/kg reduced creatinine clearance by approximately 90%, clofibric acid plasma clearance by approximately 60%, clofibric acid glucuronide renal clearance by approximately 85% and increased the time averaged plasma concentration of clofibric acid glucuronide approximately by 6-fold, compared to control values. Fifty percent of administered clofibric acid glucuronide is hydrolyzed to clofibric acid in rabbits with normal renal function. These studies support a mechanism for the renal function dependent plasma clearance of clofibric acid involving a futile cycle in which the net plasma clearance of clofibric acid is determined by the conjugation of clofibric acid and competition between renal clearance and hydrolysis of the ester glucuronide.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6655566

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  18 in total

Review 1.  Physiologically-based pharmacokinetic modeling for absorption, transport, metabolism and excretion.

Authors:  K Sandy Pang; Matthew R Durk
Journal:  J Pharmacokinet Pharmacodyn       Date:  2010-12-14       Impact factor: 2.745

Review 2.  The role of beta-glucuronidase in drug disposition and drug targeting in humans.

Authors:  B Sperker; J T Backman; H K Kroemer
Journal:  Clin Pharmacokinet       Date:  1997-07       Impact factor: 6.447

Review 3.  Enantioselective pharmacodynamics and pharmacokinetics of chiral non-steroidal anti-inflammatory drugs.

Authors:  A M Evans
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

Review 4.  Variability in response to NSAIDs. Fact or fiction?

Authors:  R O Day; G G Graham; K M Williams; P M Brooks
Journal:  Drugs       Date:  1988-12       Impact factor: 9.546

Review 5.  Drug interactions involving aspirin (acetylsalicylic acid) and salicylic acid.

Authors:  J O Miners
Journal:  Clin Pharmacokinet       Date:  1989-11       Impact factor: 6.447

6.  Comparison of paracetamol metabolism in young adult and elderly males.

Authors:  J O Miners; R Penhall; R A Robson; D J Birkett
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

7.  Stereoselective pharmacokinetics of ketoprofen and ketoprofen glucuronide in end-stage renal disease: evidence for a 'futile cycle' of elimination.

Authors:  N G Grubb; D W Rudy; D C Brater; S D Hall
Journal:  Br J Clin Pharmacol       Date:  1999-10       Impact factor: 4.335

8.  The disposition of ketoprofen enantiomers in man.

Authors:  B C Sallustio; Y J Purdie; A G Whitehead; M J Ahern; P J Meffin
Journal:  Br J Clin Pharmacol       Date:  1988-12       Impact factor: 4.335

9.  Mechanistic modelling of tesaglitazar pharmacokinetic data in subjects with various degrees of renal function--evidence of interconversion.

Authors:  Bengt Hamrén; Hans Ericsson; Ola Samuelsson; Mats O Karlsson
Journal:  Br J Clin Pharmacol       Date:  2008-02-21       Impact factor: 4.335

Review 10.  The problems and pitfalls of NSAID therapy in the elderly (Part II).

Authors:  A G Johnson; R O Day
Journal:  Drugs Aging       Date:  1991-05       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.